If the proposed Advanced Research Projects Agency for Health is created, new treatment candidates would need to engage with FDA early on to help determine appropriate clinical testing design, FDA principal deputy commissioner Janet Woodcock said Monday at the Reagan Udall Foundation for the FDA’s annual public board of directors meeting. Read more here.